Should pharmaceutical companies disclose Transfers of Value made for market research?

Clause 24.5 requires that companies must publicly disclose annually, details of payments made to contracted individuals in relation to market research (unless the company concerned does not know the identities of those participating in the market research). The supplementary information to Clause 24.5 qualifies this and states that it relates only to market research using contracted individuals where the pharmaceutical company knows the identity of the contracted individuals. This is because the focus of the requirements concerning transparency is on areas where there are direct relationships between the parties and that is not so where the company does not know the identity of the participants.